Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11241470 | 0.98 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1CA1CA2MEN1 | |
| SCHEMBL707695 | 0.93 | — | — | |
| SCHEMBL6839658 | 0.92 | MEN1 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8773639 | 0.86 | — | — | |
| SCHEMBL17666834 | 0.84 | — | — | |
| SCHEMBL14861960 | 0.84 | — | — | |
| SCHEMBL333316 | 0.77 | — | — | |
| SCHEMBL11254984 | 0.75 | — | — | |
| SCHEMBL17666835 | 0.75 | — | — | |
| SCHEMBL11254990 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154956-A1 | GLUCAGON ANTAGONISTS | Ligand Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191900-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| JP-2012500212-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | claimed |
| EP-3006543-B1 | POLYFUNCTIONAL LUBRICANT COMPOSITION | ADEKA CORP (JP) | 2021-05-26 | — | — | EP | disclosed |
| CN-105339473-B | Multifunctional lubricant composition | 株式会社ADEKA | 2018-01-02 | — | — | CN | disclosed |
| US-9738848-B2 | Polyfunctional lubricant composition | ADEKA CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| EP-3154956-A1 | GLUCAGON ANTAGONISTS | Ligand Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160122679-A1 | POLYFUNCTIONAL LUBRICANT COMPOSITION | ADEKA CORPORATION (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3006543-A1 | POLYFUNCTIONAL LUBRICANT COMPOSITION | Adeka Corporation (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-105339473-A | Polyfunctional lubricant composition | ADEKA CORP | 2016-02-17 | — | — | CN | disclosed |
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-4282171-A | Phosphorus and sulfur containing amides and thioamides | THE LUBRIZOL CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
| US-4208357-A | Process for preparing phosphorus and sulfur containing amides and thioamides | THE LUBRIZOL CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-4032461-A | PHOSPHORUS AND SULFUR CONTAINING AMIDES AND THIOAMIDES AS LUBRICATING OIL ADDITIVES AND LUBRICATING OIL COMPOSITIONS CONTAINING SAME | THE LUBRIZOL CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4031023-A | Lubricating compositions and methods utilizing hydroxy thioethers | THE LUBRIZOL CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | ALDH1A1 356/4885L3MBTL1 527/4885CA1 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.